Novome is engineering activities into the gut microbiome to treat chronic diseases. The gut microbiome performs many activities within the body such as food digestion and immune system regulation. Instead of discovering drugs, Novome’s approach is to build them by designing cell therapies referred to as GEMMs - Genetically Engineered Microbial Medicines. Novome’s proprietary platform is the first to colonize the gut with engineered microbes to deliver precise and controllable activities. Novome has already received promising results of their first product NOV-001 in a Phase I trial in healthy volunteers showing safe colonization. With this, Novome now plans to expand a pipeline of GEMMs for a wide range of diseases.
Claim company profile to post jobs directly on this page and this website.